Real-World Data Drives CAR T Treatment Decisions
Payers and providers are using real-world data to identify high-performing treatment centers, reduce administrative bottlenecks, and support value-based contracting arrangements.
In 2017, the first two CAR T-cell therapies — Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel) — were approved and have helped to transform treatment for blood cancer.
Since then, the two therapies have been approved for additional indications and five new CAR T-cell therapies have come to market.
As the CAR T pipeline expands into solid tumors and autoimmune diseases, the current infrastructure may struggle to meet increased demand.
Real-world data drives CAR T treatment decisions.
Author summary: Real-world data informs CAR T treatment choices.
More News
- European Market Monitor: Cars and Vans (September 2025) - International Council on Clean Transportation
- Glaude urges a simple reponse to MAGA: 'You're lying' – Baptist News Global
- Eating ultra processed food could cause changes to the brain which could drive overeating
- BFUHS commences round 1 NEET PG counselling 2025 registrations, check complete schedule here
- GRID Powers Up: XSite Braehead Unveils Bold New Identity
- Andy Cohen Praises a Dallas Church for its Reponse to Gov. Abbott's War on Crosswalks
- Tracking cold, wet and gusty Wednesday morning conditions
- 28,760 MD, MS, PG Diploma, DNB seats available for NEET PG 2025 Counselling- MCC seat matrix OUT!
- Elaine Hendrix on Vegan Living, ‘Dancing With the Stars’, and Life After ‘The Parent Trap’
- Inside India’s RSS, the legion of Hindu ultranationalists